The PI3K/mTOR pathway is frequently found constitutively activated in ALL [35, 36, 59] and targeted inhibition of mTOR, alone or in association with PI3K, has been investigated at multiple levels, generally displaying better results in vitro than in vivo. Here, MTOR is linked to acute lymphoblastic leukemia.